Solventum stock
Price history
+6.28% over the period1 year: from $79.51 (November 20, 2025) to $84.50 (November 20, 2026), +6.28%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $84.50 |
| October 30, 2026 | $81.33 |
| September 30, 2026 | $88.15 |
| August 31, 2026 | $91.06 |
| July 31, 2026 | $85.44 |
| June 30, 2026 | $77.15 |
| May 29, 2026 | $74.95 |
| April 30, 2026 | $67.36 |
| March 31, 2026 | $65.30 |
| February 27, 2026 | $74.20 |
| January 30, 2026 | $76.97 |
| December 31, 2025 | $79.24 |
| November 28, 2025 | $85.26 |
| November 20, 2025 | $79.51 |
At a glance
The company
Develops and sells medical devices, dental products, and healthcare software solutions for wound care, surgical supplies, orthodontics, and clinical documentation
Latest results
Quarter to September 30, 2026 · EPS $1.45 (estimate $1.62)
TickerLandia's take on Solventum
- Pricier than similar companies: trailing 12-month P/E 95 vs 34 (+181%) in a group of 9.
- Strong point: Market momentum (63/100 in its group). Weak point: Financial strength (13/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−10.26% from the 52-week high
Analysts · 15 analysts
Average target$98.38+16.43% vs. price
Buy 8 · Hold 5 · Sell 2 · Buy
TickerLandia Fingerprint: Solventum
Compared with similar companies: very low financial strength and very low growth.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 888 North American stocks.
Priceaverage47
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 94.9 95 Forward P/E 11.2 4 EV/EBITDA 19.1 66 Price/book 2.99 43 Price/sales 1.76 25 Profitabilitylow21
How much it earns on revenue and capital.
Metric Value Position in group Net margin 1.9% 16 Gross margin 53.8% 51 Operating margin 5.9% 10 ROE 3.2% 16 ROA 2.1% 10 Earnings stabilityaverage44
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 6.1% 25 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthvery low15
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) −7.00% 7 Average revenue growth (3 years) +0.79% 22 Financial strengthvery low13
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 1.10 17 Interest coverage 1.95 5 Current ratio 1.03 16 Net debt/EBITDAcounts in reverse: lower means more financial strength 3.75 14 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong63
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +5.45% 57 Relative strength (6 months) +19.39% 73 1-year return +6.28% 46 Distance from 200-day average +6.84% 76 Risklow39
How much the price swings.
Metric Value Position in group Beta (1 year) 0.64 48 Volatility (60 days) 26.2% 25 Maximum drawdown (12 months) 27.5% 45
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Solventum is pricier than similar companies
Solventum's P/E (trailing 12 months): 94.9, +181% against the median of a group of 9 similar companies (33.8).
Compared with 9 similar companies
| Metric | Solventum | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 94.9 | High | |
| Forward P/E | 11.2 | Low | |
| Operating margin | 5.9% | Low | |
| ROE | 3.2% | Low | |
| Debt/equity | 1.10 | High |
Grey band: the middle half of the group; tick: the median; dot: Solventum. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.95B
Latest quarter · Q3 2026
Net income
-$12M
Latest quarter · Q3 2026
Quarterly net margin
-0.6%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $14.36B
- P/E
- 94.9
- EPS
- $0.89
- Volume
- 658.35K
- Daily trading
- €97.29M
- Dividend yield
- 0.00%
How Solventum is changing
All resultsRevenue grew 2.7% a year on average over the last 5 years
Operating margin fell from 20.8% to 8.1%
Free cash flow equal to 72% of net income
Returns
Solventum returns
$1,000 invested in Solventum 1 year ago, on November 20, 2025, would be worth $1,063 today: +6.28% in total, +6.28% per year. This is the price return only: dividends are excluded.
| Period | Solventum | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −2.19% | −10.40% | $978 |
| 6 months | +10.99% | −7.03% | $1,110 |
| Year to date | +6.64% | +0.95% | $1,066 |
| 1 year | +6.28% | +5.68% | $1,063 |
Over the last 6 months it has done better than 50% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Solventum: technical analysis
Solventum shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 8.6% below its all-time closing high ($92.44, September 3, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 42
- Between 30 and 70
- vs 200-session average
- +6.84%
Support and resistance
Price areas where Solventum has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$92.49+9.45%2 touches, last on November 6, 2026
- Resistance$89.24+5.61%5 touches, last on October 15, 2026
- Resistance$86.45+2.30%2 touches, last on September 18, 2026
- Last price$84.50
- Support$83.01−1.76%4 touches, last on October 13, 2026
- Support$80.47−4.77%5 touches, last on October 30, 2026
- Support$77.61−8.15%3 touches, last on July 23, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.64
- Volatility (60 sessions, annualised)
- 26.2%
- Largest fall in the last year
- −27.46%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Solventum and its competitors
Healthcare systems, dental professionals, patients and original equipment manufacturers in the United States and abroad are the customers Solventum serves. The company develops, manufactures and sells wound care products such as negative pressure wound therapy and advanced wound dressings, surgical supplies, sterilization assurance and temperature management solutions, and medical tapes and wraps.
- Headquarters
- Eagan, United States
- Employees
- 20,584
- Founded
- 2023
- Chief executive
- Bryan Hanson
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| SolventumSOLV | $14.36B | 5.9% | 94.9 | +10.99% |
| Baxter InternationalBAX | $13.14B | 7.6% | — | +35.27% |
| Cooper CompaniesCOO | $11.2B | 12.9% | 20.2 | −4.65% |
| Align TechnologyALGN | $10.94B | 19.6% | 22.6 | −5.03% |
| RepligenRGEN | $10.89B | 8.1% | — | +46.60% |
| AvantorAVTR | $10.06B | 8.0% | 29.7 | +88.32% |
Same industry or related industries, similar size. Compare Solventum with its competitors · Full profile
